ClinicalTrials.gg
CompletedNCT03897309VXA-NVV-103Updated Sep 21, 2022

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

A Phase 1 interventional study of VXA-G1.1-NN and VXA-G2.4-NS in Norovirus Infection, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Vaxart · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.

Enrollment
4th of 11
86 · median 60
Started
2019
the only one that year
Phase 1
6 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
7 of 11
Vaxart

Among the 11 studies in Caliciviridae Infections with a site in United States, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 1, and was the 5th registered.

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

Browse Caliciviridae Infections studies →

Open to participants now

None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →

Who these studies take

Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Caliciviridae Infections with a site in United States as a file.
02

Study summary

VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 with Monovalent or Bivalent Dosing in Healthy Adult Volunteers. The study consists of 2 parts: Part 1 is the double-blinded portion where subjects will be randomized to one of two monovalent vaccine groups, bivalent vaccine group or placebo. Subjects will be followed for \~4 weeks post vaccination for safety and immunogenicity. Part 2 will consist of an open label booster vaccination for the bivalent treatment group \~4 months post initial vaccination. All subjects will be followed for long term safety for 1 year post initial vaccination.

Read the detailed description

VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 with Monovalent or Bivalent Dosing in Healthy Adult Volunteers. The study consists of 2 parts with will enroll 86 subjects:

Part 1 - Double Blind Period: Post confirmation of eligibility subjects will be randomized in a double-blinded manner to one of four treatment arms. Treatment Group 1 will contain an open-label sentinel group of 6 subjects to be enrolled prior to initiation of subsequent treatment groups. After review of the safety data and confirmation the dose is well tolerated through Study Day 8, the rest of the study will proceed in a double-blinded, randomized fashion. The 6 sentinel subjects will not be part of the 16 subjects in Treatment Group 1 to be enrolled in the double-blinded placebo-controlled cohort; randomization will be 1:1:2:1 for Treatment Groups 1 through 4 respectively.

Study Design and Vaccine Groups

  1. Monovalent GII.4 VXA-G2.4-NS (6 sentinels / 16 randomized)
  2. Monovalent GI.1 VXA-G1.1-NN (16 randomized)
  3. Bivalent GII.4/GI.1 VXA-G2.4-NS + VXA-G1.1-NN (32 randomized)
  4. Placebo Tablets no vaccine (16 randomized)

Subjects will be followed for \~4 weeks post vaccination for safety and immunogenicity. The study database will be locked post completion of Day 29 visits.

Part 2 will consist of an open label booster vaccination for the bivalent treatment group \~4 months post initial vaccination. Subjects will be followed for safety and immunogenicity for \~4 weeks post the boost.

All subjects will be followed for long term safety for 1 year post initial vaccination.

03

Conditions studied

  • Norovirus Infection
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 18 to 49 years, inclusive
  • General good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratories
  • Demonstrate comprehension of the protocol procedures and willingness to adhere to all visits and assessments
  • between 17 and 35 at screening
  • Female subjects must have a negative pregnancy test at screening and before each vaccination and fulfill protocol specified criteria for adequate .

Exclusion criteria

Exclusion Criteria:

  • Presence of a significant medical condition which in the opinion of the investigator precludes participation in the study
  • History of cancer or cancer treatment within past 3 years
  • Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus or angioedema
  • Donation or use of blood/blood products within 4 weeks prior to vaccination
  • Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic.
  • Any condition that resulted in the absence or removal of the spleen
  • Positive , or tests at the screening visit
  • Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days of vaccination
  • Use of medications known to affect the immune function within 14 days of vaccination
  • Use of NSAIDs, sulfonylureas, and angiotensin II blockers within 7 days of vaccination
  • Evidence of recent or of current nonbacterial gastroenteritis suggestive of NV infection to any gastroenteritis within 2 weeks of vaccination
  • History of drug, alcohol or chemical abuse within 1 year of screening or positive urine drug test at screening
  • Consistent/habitual smoking within 2 months as per medical history
  • History of or allergic reaction to any component of the vaccine or placebo
  • Use of any investigational vaccine, drug or device within 8 weeks preceding vaccination, or planned use of the above stated for the duration of the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Monovalent GI.1

    Monovalent GI.1 tableted vaccine group

    Biological: VXA-G1.1-NN · Biological: Placebo Tablets

  • Experimental
    Monovalent GII.4

    Monovalent GII.4 tableted vaccine group

    Biological: VXA-G2.4-NS · Biological: Placebo Tablets

  • Experimental
    Bivalent GI.1 and GII.4 vaccine group

    Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine

    Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS

  • Placebo comparator
    Placebo

    Placebo tablets

    Biological: Placebo Tablets

Interventions

  • BiologicalVXA-G1.1-NN

    Monovalent GI.1 tableted vaccine

    Also known as: GI.1 oral vaccine tablet

  • BiologicalVXA-G2.4-NS

    Monovalent GII.4 tableted vaccine

    Also known as: GII.4 oral vaccine tablet

  • BiologicalPlacebo Tablets

    Tablets matching in number and appearance to active vaccine doses

    Also known as: Oral tablets for control arm

06

What researchers measure

Primary outcomes

  1. Rate of Solicited Adverse Events

    Comparison of rate of occurance and severity of Solicited Adverse Events observed between treatment groups

    Time frame: Day 1 (Vaccination) to 7 days post vaccination

  2. Rate of Unsolicited Adverse Events

    Comparison of the rate of occurrence and severity of unsolicited Adverse Events observed between treatment groups

    Time frame: Day 1 (Vaccination) to 28 days post vaccination

  3. Immunogenicity - VP1 Specific IgA ASC

    LS Mean difference in VP1 specific IgA ASC between vaccine and placebo group

    Time frame: Day 1 (vaccination) to 7 days post-vaccination

  4. Immunogenicity - BT50 Assay

    Difference in HBGA blocking antibodies (by blocking titer fifty assay \[BT50\]) between vaccine and placebo groups

    Time frame: Day 1 (vaccination) to 28 days post-vaccination

Secondary outcomes

  1. Immunogenicity - VP1 specific serum IgG

    LS Mean difference in VP1 specific serum IgG between vaccine and placebo groups

    Time frame: Day 1 (vaccination) to 7 days post-vaccination

07

Study locations

1 site
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
08

References and documents

Individual participant data

Plan to share: No — Study results will be summarized and presented by treatment arm comparisons. Individual subject data will not be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jan 2021, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Apr 1, 2019
StartActual
Mar 20, 2019
Primary completionActual
Jan 15, 2021
CompletionActual
Apr 1, 2021
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03897309
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Mar 20, 2019
Primary completion
Jan 15, 2021
Completion
Apr 1, 2021
Last update
Sep 21, 2022

Study contacts

Mary Beth Manning, MD
principal investigator · Rapid Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion